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Abstract 
Objective: To study in guinea pigs knee joints the effects of intra-articular 
injection of HYADD®4-G (Fidia- Farmaceutici), a novel hyaluronan-derived 
elastoviscous material and of Hyalgan® (Fidia- Farmaceutici), a hyaluronan 
product with very low viscoelasticity, on movement-evoked nociceptor impulse 
activity from normal and inflamed knee joints. 
Design: Nociceptor impulse activity was recorded from single Aδ and C fibers of 
the medial articular nerve either under control conditions or after induction of an 
experimental knee joint osteoarthritis by partial menisectomy and transection of 
the anterior cruciate ligament (PMM-TACL). The stimuli consisted of 
standardized innocuous and noxious inward and outward rotations of the tibia 
against the femur of 50 seconds duration, repeated every 5 minutes for 1.5 
hours.  
Results: The number of movement-evoked impulses was significantly 
augmented one day and one week after PMM-TACL compared with intact knee 
joint. The enhanced impulse response to joint movements one week following 
surgery was attenuated by repeated intra-articular injection of HYADD®4-G and 
even more prominently by HYALGAN®. 
Conclusions: Hyaluronan products have a reducing action on joint nociceptor 
discharges that appears to depend predominantly on their role as an 
elastoviscous filter associated with their rheological properties, but also on a 
chemical effect on sensitized nociceptive terminals of inflamed joint tissues, 
possibly linked to the hyaluronan concentration. 
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Introduction
Hyaluronan (sodium hyaluronate, HA) is a glycosaminoglycan present in joint 
tissues containing nerve terminals, i.e synovial tissue and capsule, and also in 
the surface layer of the cartilage and in synovial fluid. This highly elastoviscous 
polymer fills the intercellular space between the collagen fibrillar network, 
surrounding all of the cells, the blood and lymph vessels and the neural elements 
in the fibrous tissue of the joint 1, 2, 3.
In arthritic conditions, elastoviscosity of the synovial fluid and tissue matrices is 
abnormally low 2, 3. Thus, elastoviscous solutions of HA with variable molecular 
mass (0.5 - 6 million) have been injected intra-articularly, with the aim of restoring 
the rheological homeostasis of the joint in osteoarthritis 3, 4, 5-7. This treatment was 
called viscosupplementation 3, 5. Early human and equine clinical studies showed 
that with this treatment, the elastoviscosity of the synovial fluid returned to normal 
levels and simultaneously, the pain associated with the movement of the joint 
decreased or was completely eliminated 6, 8, 9. 
It has been hypothesized that intra-articular HA application causes analgesia by
increasing the elastoviscosity of the intercellular matrix of soft tissues around the 
joint, thus providing a rheological buffer that reduces the force transmitted during
joint movements to the transducing membrane elements at sensory nerve
terminals innervating the synovial lining and capsule. This proposal was 
supported by experimental studies showing that intra-articular injection of high 
elastoviscous HA solutions produced a reduction of movement-induced nerve 
impulse activity in single nociceptor fibres of normal and acutely-inflamed knee 
joints of cats, rats and guinea pigs 10-14. Molecular mass of HA solutions seems
to play an important role in this effect because injection of non-elastoviscous 
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solutions of low molecular mass did not cause a decrease of pain, nor of 
nociceptor activity in experimental animals 7, 10, 12.
The recording from single fine articular afferents of the knee joint while applying 
knee joint movements of defined torque 15, opened up the possibility to evaluate 
quantitatively the analgesic effects of hyaluronan preparations of various 
compositions on normal joints or on joints of animals subjected to partial medial 
menisectomy (PMM) and transection of anterior cruciate ligament (TACL), a 
condition that has been claimed to mimic an osteoarthritic condition.
Consecutive to this surgery, joint inflammation was present as evidenced by an 
increase in knee joint diameter, possibly reflecting an excess of volume of 
synovial fluid (exudate) that persisted for 3 weeks. In parallel, an augmented 
nerve response to knee joint movement was observed 1 day and 1 week after 
surgery 13. These responses were reduced by Hylan G-F20 a highly viscous 
Hyaluronic acid preparation. Likewise, a decrease of pain symptoms has been 
reported after intra-articular injections of hyaluronic acid of different rheology in 
osteoarthritic patients 16-20. 
In the present study, the PMM-TACL model of experimentally-induced knee joint 
osteoarthritis in guinea pigs was used to evaluate the effect on movement-
evoked impulse activity of single knee joint nociceptive nerve fibers, of a newly 
developed HA product of high elastoviscosity HYADD4®-G 21, comparing its 
analgesic effects with those of Hyalgan®, a low elastoviscosity solution of higher 
HA concentration but similar molecular weight.
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Material and methods
The study was performed on 117 guinea pigs of both sexes with ages between 
5 and 6 weeks at the time of surgery, weighing 400-450 grams. In 50 animals
more than one unit could be studied in the same experiment while in the 
remaining 67 animals, one single fiber per experiment was recorded. Animals 
were treated in accordance with institutional animal care guidelines.
PMM AND TACL SURGERY 
Partial medial menisectomy plus transection of the anterior cruciate ligament 
were performed in the right hind limb, as a model to induce joint inflammation, 
and joint instability leading to OA lesions 22-29. In brief, animals were 
anesthetized with an intramuscular injection of a mixture of ketamine (50 mg/kg) 
and xilacine (10 mg/kg). Anesthesia was maintained using isofluorane (1-1.5 %) 
mixed with 0.5 l of oxygen administered through the respiratory circuit. An 
antero-medial approach to the joint was achieved via a skin incision extending 
from the level of the distal third of the femur to the proximal fourth of the tibia. 
The skin was retracted and the joint capsule opened. The medial meniscus was 
identified and transected halfway between its anterior and posterior horns. The 
anterior cruciate ligament was transected afterwards. The joint capsule and the 
overlying fascia were subsequently sutured.
Sham operated animals were treated identically except that transections of the 
meniscus and of the anterior cruciate ligament were omitted.
To accelerate the recovery of the animals, they received an injection of 5 mg/kg 
atipamezol (a xilacine reversing agent). For three days after surgery, 
subcutaneous injections of buprenorphine HCl (an analgesic acting at CNS 
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level) and enrofloxacine (an antibiotic) were applied per day. The knee joint 
circumference was routinely measured before surgery and at the onset of the 
experimental procedures for the recordings from the nerve filaments of the 
various experimental groups. The animals were maintained in the animal house 
for variable periods of time (from 24 hours up to one week) prior to the nerve 
recording session. During this time they were allowed to move freely, drinking 
and eating ad libitum. 
RECORDING PROCEDURES
The animals were anaesthetized initially with an intramuscular injection of a 
mixture of Ketamine (50 mg/kg) and Xilacine (10 mg/kg. Supplementary doses 
of anesthetic were injected i.v as required. Animals were paralyzed by the i.v. 
administration of 5 mg/100 g gallamine triethiodide i.v. (Sigma) and artificially 
ventilated. Body temperature was kept around 37ºC with a servoregulated 
heating pad.
All recordings were done on the right hindlimb. The surgical preparation 
followed the routine pattern worked out in this laboratory over the last years 11-
13, 15. A tracheotomy was performed. Cannulations of the left femoral vein and 
artery were also made to apply substances and to control blood pressure. An 
additional fine catheter was placed into the right saphenous artery distal to the 
knee joint for close retrograde i.a. application of KCl into the joint area.
Stabilization of the right femur was accomplished by fixation with a special grip, 
and a pool was formed using skin flaps which was filled with warm paraffin oil. 
In this pool the whole medial part of the leg was exposed, including the knee 
joint and the patellar ligament. A shoe-like holder for the hind paw was 
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connected to a lever via a metal rod equipped with a strain gauge and a torque-
meter (Hottinger Baldwin Messtechnik, Germany) to measure the applied torque 
when performing inward and outward rotations of the calf against the thigh.
The recording techniques were analogous to those used in previously 12, 13. In 
brief, the saphenous nerve was cut both in the inguinal region and distally from 
the joint, leaving only the medial articular nerve intact. Fine filaments were 
dissected at the proximal end of the nerve. After putting the filaments over a 
silver wire electrode for extracellular recording, the receptive fields of the 
afferent units were explored by recording the nerve impulse responses to 
mechanical stimuli evoked by probing the tissue over the knee joint and its 
surroundings with a hand-held glass rod.
The afferent terminal of the nerve fiber so identified was electrically stimulated 
(5-15 V, 0.5 ms) within its receptive field to calculate the conduction velocity 
from the latency of the evoked impulse and the distance between the 
stimulating and recording electrodes. Nerve fibers with conduction velocities 
<2.5 m/s were classified as C-fibers, those with conduction velocities from 2.5 to 
20 m/s as A-fibers 13.
In order to ensure that the units under observation were being reached by the 
blood supply to the medial aspects of the knee joint and remained functional, 
their discharges in response to a close intra-arterial bolus injection of KCl (0.2
ml, 0.3 M, via the catheter in the A. saph., see above) were observed at the end 
of the recording period.
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STIMULATING PROCEDURES
The mechano-sensitivity to knee joint movements of all articular afferent units 
identified in this way was explored using a movement protocol (see 12), starting 
from the middle (the normal resting) position of the joint. It consisted of a 
passive, manually performed outward rotation within the working range of the
joint of 10 s duration (10 to 20 mNm, innocuous outward rotation, [OR]) followed 
by an equally long outward rotation which exceeded the normal working range 
of the joint (40 to 60 mNm, noxious outward rotation, [NOR]). Thereafter, the 
joint was returned to the resting position for 10 s and the same two steps were 
performed using innocuous and noxious inward rotations [IR and NIR]. Such a 
complete movement cycle ([OR, NOR] followed by [IR, NIR]) with a total 
duration of 50 s was repeated every 5 minutes (see plots in Figs. 1 - 3). The 
rotation called innocuous occurs in the normal working range of the knee joint; it 
is not made against resistance and it evokes a very discrete or no activity in 
joint afferent units 15, 30.
EXPERIMENTAL DESIGN
The following 8 experimental groups were made, according to the treatment 
received (see also Table 1)
Group 1.  Healthy animals.
Group 2.  Healthy animals that received 1 intra-articular injection  of  saline    
solution 1 day before nerve recording.
Group 3.  Healthy animals that received 1 intra-articular injection of HYADD4-
G® 1 day before nerve recording.
Group 4.  Animals with sham surgery performed   one   day and 1 week before 
nerve recording.
Group 5.  Animals   with   PMM-TACL   surgery performed   one   day   and 1  
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week before nerve recording.
Group 6. Animals  with  PMM-TACL  surgery  together with  immediate  intra-
articular injection  of  HYADD4-G® ,  recorded  one  day  after  surgery,  and 
animals   with   PMM-TACL   surgery  that   received   2  intra-articular injections 
of HYADD4-G®, one at the end of the PMM-TACL surgery and one 3 days later
(at day 4, i.e. at the 3rd postoperative day). Articular nerve fiber recording was 
performed one week after surgery. 
Group 7.  Animals   with   PMM-TACL   surgery   that received 2 intra-articular 
injections of saline solution, one at the end of the PMM-TACL surgery and one 
3 days later. Articular nerve fiber recording was performed one week after 
surgery.
Group 8. Animals that received 2 intra-articular injections of Hyalgan® solution, 
one at the end of the PMM-TACL surgery and the second, 3 days later. Articular 
nerve fiber recording was performed at day 7 after surgery.
TEST MATERIAL(S) AND THEIR APPLICATION
Two hyaluronan products were used: Hyalgan® and HYADD®4-G. Hyalgan® is a 
10 mg/ml solution of 500.000-730.000 average molecular weigh hyaluronic acid.
HYADD4®-G, is the hexadecylamide of hyaluronic acid of 500.000-730.000
average molecular weigh (5mg/ml), obtained through chemical modification of 
500.000-730.000 average molecular weigh hyaluronic acid by adding 
hexadecylamine (a primary aliphatic amine with 16 carbon atoms) to the 
carboxilic group of glucuronic acid. According to the manufacturing company, 
FIDIA-Farmaceutici the degree of modification is very low (2% mol/mol), that 
means that in HYADD®4-G, of every 100 (disaccharide) units of hyaluronic acid
(N- acetyl glucosamine and D-glucuronic acid) only 2 have D-glucuronic acid 
chemically modified by the covalent bound to the  hexadecylamine.  FIDIA 
claims that this chemical modification determines a relevant increase of the 
viscoelastic properties in comparison to the starting Hyalgan® and that at 2.5 Hz 
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the elastic modulus of 5 mg/ml HYADD®G is about 50 Pa while the elastic 
modulus of Hyalgan® is 0.6 Pa.
In this study, Hyalgan® was used as available in the market, therefore at 10 
mg/ml in PBS, while HYADD®4-G was used at a concentration of 5 mg/ml in 
PBS. 100 μl of the test material and of the control saline solution were injected 
into the joint space from the lateral side using a 26G needle. This was followed 
by passive knee joint movements to facilitate the intra-articular distribution of 
the solution. 
ACTIVITY MEASUREMENT
The discharges recorded during the movements were analyzed by counting 
separately the number of impulses evoked by each of the four movements 
OR+NOR+IR+NIR. The regular observation was that the change of the nerve 
activity, depending on the treatment group, occurred both during movements 
performed within the working range and in the noxious range.  For this reason, 
we used the discharges recorded during the complete movement cycle for 
presentation of the results. Plots and graphs displayed in the figures were 
averaged from at least 8 individual experiments (for details see legends). The 
numbers of fibers recorded in each experimental condition is indicated in Table 
1.
STATISTICS
For statistical evaluation, the total number of impulses obtained during the 
complete cycle was used to represent the response to each individual 
movement. They were then pooled to find the mean ± SEM representing the 
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average response of each experimental group. Comparison between mean 
values of the different experimental groups of animals was performed using the 
One-Way ANOVA. Individual values of knee joint circumferences before and 
after surgery were compared using the Student’s paired t-test. The significance 
level was set at P < 0.05 (*).
Results
General findings
Successful recordings of appropriate duration (> 90 min) were obtained 
from 174 fine afferent nerve fibers of the median articular nerve (MAN) of 117 
animals belonging to the various experimental groups. Most of the MAN nerve
fibers of the guinea pig responding to movements of the knee joint had 
conduction velocities (CV) that included them either into the A-delta (CV = 2.5-
20 m/s, fine myelinated fibers) or the C-fiber group (CV = < 2.5 m/s, 
unmyelinated fibers). Unequivocal determination of the CV was possible for 62
A-delta (mean CV= 3.8 ± 0.2 m/s) and 68 C-fibers (mean CV= 1.64 ± 0.1 m/s).
The number of C and A fibers was variable among groups making difficult in 
some cases statistical comparisons. Moreover, observed changes in nerve 
activity with treatment occurred equally in A and C fibers. Therefore data from
A and C fibers have been presented jointly in the results.
Effect of HYADD4-G on movement-evoked activity in healthy knee joints
The solid square symbols in Fig. 1A represent the average activity of 18 single 
units from healthy animals evoked by innoxious (20 mN) and noxious (65 mN) 
outward and inward rotations. Each point represents the average number of 
impulses evoked by a complete movement cycle that had a total duration of 50 
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s.
The filled triangles symbols in Fig. 1A show the movement-evoked impulse 
activity measured in recordings performed in 10 afferent fibers, 24 h after intra-
articular injection of 100 μl of HYADD®4-G while open circles represent the 
average, movement-evoked impulse discharge in 10 additional fibers measured 
24 hours after injection of 100 μl saline. To perform the injections into the joint 
cavity the animals were briefly sedated by an intramuscular injection of 
ketamine. The bar histogram in Fig. 1B illustrates the summarized results of 
these experiments, and show that both types of intra-articular injections reduced 
in a significant way the average discharges of the primary afferent units evoked 
by knee rotation. However, the injections of HYADD®4-G led to a much more 
pronounced discharge decline than that of the saline application. Data are 
summarized in Table 1.
Movement-evoked activity in primary knee joint afferents after sham- and PMM-
TACL- operations. 
The open squares in Fig. 2A illustrate the data obtained from 11 single fine 
articular units after PMM-TACL surgery performed one day before the beginning 
of the electrophysiological recording. The black squares in this plot display the 
results of 12 similarly conducted experiments except that sham-surgery was 
performed, (for details see methods). Obviously the PMM-TACL surgery led to a 
significant increase (24% on average) in the evoked afferent outflow from the 
fine articular afferents (Table 1).
Fig. 2B illustrates a set of similar experiments conducted one week after the 
surgical procedures. One week after PMM-TACL surgery there is -in 
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comparison to the outflow from the sham operated joints- still a considerable 
increase in the evoked impulse outflow from the fine articular afferents (Table 
1). Results of these 2 sets of experiments are summarized in the grey and white 
bar histograms of Fig. 2C.
Movement-evoked activity after intra-articular injection of HYADD®4-G and 
Hyalgan® in PMM-TACL knee joints
When immediately after PMM-TACL surgery a dose of 100 μl of HYADD®4-G 
was injected into the joint cavity the afferent outflow recorded one day later was 
significantly reduced as illustrated by the filled triangles in Fig. 3A and the grey 
bar histogram in Fig. 3C (n = 18). A comparable result was obtained when 
HYADD®4-G was given at the time of operation and additionally at day 4, i.e. 
the 3rd postoperative day, and the neural activity was evaluated 1 week after the 
initial joint surgery (filled triangles in Fig. 3B, and white bar histogram, second 
from left, in Fig. 3C, n = 19). Both outflows are again in the same order of 
magnitude and significantly below those after PMM-TACL surgery alone. Data 
are summarized in Table 1. Injection of 100 μl saline instead of HYADD®4-G 
immediately after surgery and additionally at the 3rd postoperative day also 
caused a moderate reduction of impulse activity after one week compared with 
untreated PMM-TACL animals (see Table 1). Still, the mean reduction of 
movement-evoked activity one week after surgery in PMM-TACL animals 
treated with HYADD®4-G is significantly larger than in animals injected with 
saline.
To obtain comparative data with other clinically used elastoviscous materials 
HYALGAN® was injected immediately after PMM-TACL surgery and at the 3rd
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postoperative day in another group of experiments. The average movement-
evoked afferent outflow recorded one week after surgery from 16 fine single
afferent is significantly lower that the activity recorded in operated animals 
without treatment and in animals treated with HYADD®4-G. This result is
summarized in Fig. 3C (white bar histogram at the right end of the graph) and in 
Table 1.
Spontaneous activity
As summarized in Table 1, spontaneous impulse activity was present in some 
fibers of all experimental groups except the group of healthy animals treated 
with saline and recorded one day after injection. Spontaneous activity appeared 
as occasional impulses fired during the interstimulus periods. The pattern of 
spontaneous activity in these experimental groups looked like that seen in our 
previous data 13. The incidence of spontaneous activity was low (always <1 Hz) 
and variable in all experimental groups (17-52%, see table 1). 
Variation of knee joint circumference
Confirming previous observations 13, knee joint diameter increased significantly 
after surgery both in sham-operated and PMM-TACL operated animals 
(Student’s paired t-test. P<0.001). Mean values in the different experimental 
groups are summarized in Table 1.
Discussion
The present results show that the new elastoviscous compound HYADD®4-G 
has an attenuating effect on movement-evoked nerve impulse activity from 
intact knee joints of guinea pigs and also from joints in which an experimental 
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joint injury was induced by partial menisectomy and section of the anterior 
cruciate ligament. An even more marked attenuation of the activity was also 
obtained with Hyalgan®, used for viscosupplementation treatment in human 
osteoarthritis 19.
Hyalgan® is constituted  by 500.000-730.000 average molecular weight 
hyaluronic acid and has a very low elastic modulus 12. HYADD®4-G is equally 
composed by hyaluronic acid of 500.000-730.000 but chemically modified by 
adding hexadecylamine at a low degree of substitution (2% mol/mol). The 
manufacturer (Fidia – Farmaceutici) claims that this chemical modification does 
not cause crosslinking, but the presence of the hexadecylamine determines the 
formation of additional interactions in the polymer that markedly modifies the 
rheological properties of the starting hyaluronic acid, thus making this 
hyaluronan derivative more viscous and elastic. Therefore it has been possible 
in this study to compare the nociceptive effect of two  hyaluronic acid  products 
of the same molecular weight with different viscoelasticity 21.
Our work shows that HYADD®4-G was effective in reducing the excitatory
effects of moderate and strong mechanical forces on the impulse activity in fine 
medial articular nerve afferents of the intact guinea pig knee joint. Similar
effects have been described in intact and acutely inflamed rat knee joints with a 
hyaluronan solution of high elastoviscosity, Hylan G-F 20, while low 
elastoviscosity materials as Hyalgan® were ineffective 12 thus supporting the 
interpretation that the elastic and viscous properties of polymer solutions like 
hyaluronan play an important role through their pseudoplastic and molecular 
shock absorber properties in the intact joint 31. The elastoviscous behavior 
reported for HYADD®4-G predicts that this substance also absorbs part of the 
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mechanical energy of the stimulus. This would reduce the transmission of force 
to the mechanotransduction apparatus at peripheral nociceptive endings, thus 
decreasing the stimulus force and the response of knee joint sensory fibers to 
mechanical forces, as was actually observed in the present experiments. 
HYADD®4-G and Hyalgan® also reduced significantly the augmented impulse 
activity seen in operated guinea pigs, one day and one week after PMM and 
TACL. In animals with PMM-TACL-induced injury nociceptive discharges 
evoked by movement remained enhanced only during the early postsurgery 
period. This suggests that augmented activity is due to a sensitization of joint 
nociceptors secondary to the inflammatory reaction induced by the surgical 
trauma, but probably also by cartilage damage that is already observed 1-2 
weeks following surgery 32, 33. The attenuation by HYADD®4-G of this effect 
cannot be attributed primarily to the elastoviscous buffering action of this 
substance on mechanical forces transmitted to nociceptive endings because
our work now shows that one week after surgery, Hyalgan® was even more 
effective than HYADD®4-G in spite of its low elastoviscosity perhaps due to its 
comparatively higher concentration in HA molecules. 
It has been repeatedly suggested that part of the analgesic effect of hyaluronan 
products is due to their binding with the cell membrane receptors and/or 
chemical interaction with inflammatory mediators released by injured tissues 
and by inflammatory cells 1, 34-37. Chemical interaction with inflammatory 
mediators could explain the marked reduction of impulse activity both with
HYADD®4-G and Hyalgan® one week after surgery seen in the present 
experiments. 
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Surprisingly, saline injection also attenuated slightly the enhanced activity 
evoked by surgery, perhaps through dilution of locally-released inflammatory 
mediators. This result could be interpreted as the neurophysiological correlate 
of the slight but evident reduction in pain experienced by patients with intra-
articular injection of placebo or when knee washing is combined with 
viscosupplementation therapy 38. 
It is expected that inflammatory agents play a minor role in the modulation of 
movement-evoked nociceptor activity in intact knee joints but may significantly 
contribute to its sensitization when inflammation is present as was the case in 
the present study, judging by the increased knee joint diameter found in 
operated animals. 
The PMM-TACL OA model was aimed at mimicking the symptoms of 
osteoarthritis. However, nociceptive discharges evoked by movement in 
animals after PMM-TACL, were augmented only during the early postsurgery 
period, possibly reflecting the sensitization of nociceptive afferent units 
innervating knee joint tissues caused by the inflammatory reaction secondary to 
surgery. One to two weeks after PMM-TACL surgery, cartilage damage is 
evident 32, 33. Therefore a contribution to joint inflammation of joint instability and 
altered mechanics cannot be excluded. Nonetheless, the observed changes in 
impulse activity of knee joint nociceptor fibers in the PMM-TACL OA model do 
not closely reproduce the characteristics and time course of pain experienced 
by human patients suffering from OA 12, 13, 39. Thus, extrapolation of the 
attenuating action on joint nociceptor activity of locally injected hyaluronan 
derivatives in PMM-TACL-induced OA to the analgesic action of these 
compounds seen in human OA must be made with caution. Taking these 
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limitations into account, it appears reasonable to speculate that hyaluronan 
products have a direct reducing effect on joint nociceptor activity in part due to 
its role as a mechanical filter that is associated to its rheological properties but 
also to chemical interaction with inflammatory mediators present in the inflamed 
joint tissues, thus reducing their sensitizing effect on nociceptor terminals.   
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    Table 1 
 
 
 
Experimental groups 
Average number of 
impulses/movement 
cycle (s.e.m.) 
Nº of 
fibers/Nº  
of animals 
  Fibers        
  presenting  
 spontaneous 
activity (imp/s > 
0.05) 
Joint  
circumference   
(cm) 
Before/After PMM-
TACL 
1   Healthy animals              211 ± 3 
 
18 / 16 
 
4 / 18 - 
2   Healthy animals +     
     saline   One day 191 ± 1.1 10 / 6 0 / 10 - 
3   Healthy  animals +   
     HYADD4-G® One day 73 ± 1 10 / 5 3 / 10 - 
One day 198 ± 4 12 / 10 5 / 12 6.5 ± 0.1 / 7.5 ± 0.3 4   Sham- operated One week 126 ± 1.5 9 / 9 2 / 9 6.5 ± 0.3 / 7.1 ± 0.2 
 
One day 
 
246 ± 2.3 11 / 7 2 / 11 6.7 ± 0.2 / 7.5 ± 0.2  5   PMM-TACL One week 239 ± 4 15 / 10 2 / 15 6.9 ± 0.2 / 7.7 ± 0.1 
 
One day 
 
193 ± 2 
 
18 / 10 
 
3 / 18 6.3 ± 0.1 / 7.6 ± 0.2 6   PMM-TACL +  
     HYADD4-G® One week 183 ± 2.2 19 / 9 
 
10 / 19 6.3 ± 0.1 / 7.2 ± 0.2 
7   PMM-TACL + saline   
     
One week 218 ± 3.3 8 / 5 2 / 8 6.2 ± 0.1 / 7.5 ± 0.3 
8   PMM-TACL +     
     Hyalgan® 
One week 98 ± 2.2 16 / 10 3 / 16 6.5 ± 0.3 / 7.6 ± 0.1 
Table 1
Figure legends 
Fig.1. Movement-evoked activity in healthy knee joint afferents and in afferents 
24 h after saline or HYADD4-G injection into the articular cavity.  (A) Squares: 
average number of impulses recorded from primary afferent units innervating 
healthy knee joints (n = 18); circles: those of units from healthy knee joints 
which 1 day before recording received an intra-articular injection of 100 μl of 
saline (n=10); and the triangles are from units of joints which one day before 
recording received an intra-articular injection of 100 μl of HYADD4-G (n=10). 
Each point plotted shows the average ± SEM of the total number of impulses 
obtained in single primary fine afferent units during a complete movement cycle 
i.e. OR + NOR + IR + NIR, each cycle starting 5 min after the previous one and 
lasting 50 s (s. Methods for a detailed description of a movement cycle) 
obtained. (B) The bar histograms illustrate the comparison between the three 
experimental conditions. The ** denote the significance for the treated animals 
versus control (One way ANOVA; Kruskal-Wallis test P<0.001). 
 
Fig. 2. Movement-evoked activity in primary knee joint afferents after sham- 
and PMM+TAC- surgery. Stimulating, recording, evaluating and plotting as in 
Fig. 1. (A) Average movement-evoked activity in sham (solid squares; n=12) 
and in PMM + TACL (open squares; n= 11) operated animals recorded 1 day 
after surgery. (B) Average movement-evoked activity in sham (solid circles; 
n=9) and in PMM + TACL (open circles; n=15) operated animals recorded 1 
week after surgery. (C) Summary of the averages of impulses/movement cycle 
in the indicated experimental conditions.  The ** denote the significance for the 
Figure Legends
PMM + TACL animals versus sham animals (One way ANOVA; Dunn’s 
methods; P<0.001). 
 
Fig. 3. Movement-evoked activity after PMM + TACL surgery recorded one day 
or one week later and having one respectively two postoperative applications of 
either HYADD4-G or  saline or hyalgan. Stimulating, recording, evaluating and 
plotting as in Fig. 1. (A) Average movement-evoked activity recorded 1 day after 
surgery in PMM + TACL operated animals (squares; n=11) and in animals 
which in addition to the PMM + TACL surgery received an injection of HYADD4-
G (solid triangles, n=18) immediately after surgery. (B) The graphs correspond 
to those in (A), but the recordings were done one week after PMM + TACL 
surgery.  The circles plot the results obtained after surgery alone (n = 15), and 
the triangles give the results obtained when HYADD4-G (n = 19) was applied 
immediately after surgery and at the 3rd postoperative day. (C) Bar histograms 
of the results plotted in (A) and (B) as indicated by the lettering. The 3rd white 
bar at the extreme right shows the average movement-evoked afferent outflow 
one week after PMM + TACL surgery from 16 units where HYALGAN was 
injected immediately after surgery and at the 3rd postoperative day. The ** 
denote the significance for the PMM + TACL operated animals versus those 
with additional applications as indicated (One way ANOVA P<0.001). 
 
Table 1. Mean values of the number of impulses per movement cycle and 
number of fibers and animals used in each group are indicated. Also the 
spontaneous activity recorded in the different experimental groups is shown. 
The presence of spontaneous activity was consider when the number of 
impulses per second was higher than 0.05. Last column indicate average of the 
knee joint circumference measured immediately before surgery and at the day 
of the recording.  
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